Precision Medicine Startup Radence Launches Comprehensive Health Monitoring Service

Radence, a new precision medicine startup, has entered the healthcare technology space with a bold promise: early disease detection and prevention through advanced diagnostics and personalized health monitoring. The company, which describes its offering as "concierge science," aims to provide a 360-degree view of an individual's health using a combination of cutting-edge technologies and data analysis.

Comprehensive Health Profiling at a Premium

Radence's service integrates multiple data sources to create a detailed health profile for each member. This includes:

• Genomic analysis to map inherited risks
• Advanced blood panels for proteomic and metabolomic data
• Imaging studies
• Wearable device data
• Microbiome analysis
• Medical history evaluation

The company emphasizes that it is not a longevity clinic or a testing facility, but rather a service that uses extensive data collection to inform personalized care delivery. This comprehensive approach comes at a significant cost: members must commit to an annual fee of $50,000, plus a one-time $50,000 enrollment fee per family.

Collaboration with Healthcare Providers

Under the leadership of Chief Medical Officer Julie Chen, M.D., Radence aims to work alongside members' existing healthcare teams. The company analyzes collected data and collaborates with care providers to develop and update treatment plans based on ongoing monitoring and new research findings.

"Together, this creates a truly comprehensive, 360-degree view of health—what's happening now, and what's coming next," Chen explained. The goal is to detect subtle patterns and risks before symptoms appear, enabling early intervention and prevention of chronic diseases.

Strategic Partnerships and Future Directions

Despite being only a few months old, Radence has already secured a partnership with Mount Sinai and currently serves about three dozen members. The company is selective in accepting new patients, focusing on cases where they believe they can make a significant impact.

Radence's Clinical Advisory Board includes experts in cardiology, neurology, genetics, biomedical engineering, and data science. The startup is backed by RA Ventures, the healthcare incubator of RA Capital Management, and supported by a team of over 50 M.D.s and Ph.D.s.

Currently, Radence focuses on four primary areas:

1. Cardiovascular and neurovascular health
2. Cancer risk and detection
3. Neurological and cognitive health
4. Metabolic and hormonal health

The company plans to expand into additional disease areas in the future and is exploring potential collaborations with academic research institutions, life sciences companies, and even labor unions or federal employee groups.

As David Medvedeff, Radence CEO, stated, "Keeping people healthier for longer isn't just good medicine, it's good economics." The company's ambitious approach to precision medicine represents a new frontier in personalized healthcare, albeit one that is currently accessible only to those who can afford its premium price tag.